📇 Rhumatologue · MEREAU · (18) · Libéral

M BENOIT BAREAU

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Praticien-chercheur
9 articles scientifiques publiés — formation continue solide
Expérience confirmée
30 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
73 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 MEREAU (18)LibéralRPPS 10001985349

Expérience confirmée

30ans d'exercice (thèse 1996)

📊 Reconnaissance scientifique : 10/100📝 26 articles publiés🇫🇷 Publications académiques françaises (7)

✨ Génération du profil synthétique IA en cours…

Thèses universitaires

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases

Haematologica · 2010

📚 166 citations🎯 RCR 4.71Top 8% NIH🔓 Open Access📄 PDF gratuit ↗

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Nature medicine · 2024

📚 96 citations🎯 RCR 17.70Top 1% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractCD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of care (SOC). To improve current SOC, we evaluated the added value of weekly bortezomib (V) to isatuximab plus lenalidomide and dexamethasone (IsaRd versus Isa-VRd). This Intergroupe Francophone of Myeloma phase 3 study randomized 270 patients with NDMM that were TI, aged 65–79 years, to IsaRd versus Isa-VRd arms. The primary endpoint was a minimal residual disease (MRD) negativity rate at 10−5 by next-generation sequencing at 18 months from randomization. Key secondary endpoints included response rates, MRD assessment rates, survival and safety. The 18-month MRD negativity rates at 10−5 were reported in 35 patients (26%, 95% confidence interval (CI) 19–34) in IsaRd versus 71 (53%, 95% CI 44–61) in Isa-VRd (odds ratio for MRD negativity 3.16, 95% CI 1.89–5.28, P < 0.0001). The MRD benefit was consistent across subgroups at 10−5 and 10−6, and was already observed at month 12. The proportion of patients with complete response or better at 18 months was higher with Isa-VRd (58% versus 33%; P < 0.0001), as was the proportion of MRD negativity and complete response or better (37% versus 17%; P = 0.0003). At a median follow-up of 23.5 months, no difference was observed for survival times (immature data). The addition of weekly bortezomib did not significantly affect the relative dose intensity of IsaRd. Isa-VRd significantly increased MRD endpoints, including the 18-month negativity rate at 10−5, the primary endpoint, compared with IsaRd. This study proposes Isa-VRd as a new SOC for patients with NDMM that are TI. ClinicalTrials.gov identifier: NCT04751877.

Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients

Annals of oncology : official journal of the European Society for Medical Oncology · 2014

📚 56 citations🎯 RCR 1.87🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

M BENOIT BAREAU

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (9) — classées par pathologie

Biothérapies non-anti-TNF3

Transversal3

Essai clinique2

Pharmacovigilance1

Vraie vie / RWE1

Partager cette fiche